{"id":"https://openalex.org/W2970629241","doi":"https://doi.org/10.1111/bjh.16160","title":"Combinatorial ixazomib and belinostat therapy induces NFE2L2\u2010dependent apoptosis in Hodgkin and T\u2010cell lymphoma","display_name":"Combinatorial ixazomib and belinostat therapy induces NFE2L2\u2010dependent apoptosis in Hodgkin and T\u2010cell lymphoma","publication_year":2019,"publication_date":"2019-08-26","ids":{"openalex":"https://openalex.org/W2970629241","doi":"https://doi.org/10.1111/bjh.16160","mag":"2970629241","pmid":"https://pubmed.ncbi.nlm.nih.gov/31452195"},"language":"en","primary_location":{"id":"doi:10.1111/bjh.16160","doi":"https://doi.org/10.1111/bjh.16160","is_oa":true,"landing_page_url":"https://doi.org/10.1111/bjh.16160","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.16160","source":{"id":"https://openalex.org/S153015021","display_name":"British Journal of Haematology","issn_l":"0007-1048","issn":["0007-1048","1365-2141"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Haematology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.16160","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5064711111","display_name":"Frank Charles Passero","orcid":"https://orcid.org/0000-0001-7428-8826","observed_orcids":["https://orcid.org/0000-0001-7428-8826"]},"institutions":[{"id":"https://openalex.org/I28792581","display_name":"University of Rochester Medicine","ror":"https://ror.org/00trqv719","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I28792581","https://openalex.org/I5388228"]},{"id":"https://openalex.org/I5388228","display_name":"University of Rochester","ror":"https://ror.org/022kthw22","country_code":"US","type":"education","lineage":["https://openalex.org/I5388228"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Frank C. Passero","raw_affiliation_strings":["Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA","Equal contribution"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA","institution_ids":["https://openalex.org/I28792581","https://openalex.org/I5388228"]},{"raw_affiliation_string":"Equal contribution","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078559032","display_name":"Dashnamoorthy Ravi","orcid":"https://orcid.org/0000-0002-6108-2076","observed_orcids":["https://orcid.org/0000-0002-6108-2076"]},"institutions":[{"id":"https://openalex.org/I4390039325","display_name":"Rutgers Cancer Institute","ror":"https://ror.org/0060x3y55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4390039325"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dashnamoorthy Ravi","raw_affiliation_strings":["Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA","Equal contribution"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA","institution_ids":["https://openalex.org/I4390039325"]},{"raw_affiliation_string":"Equal contribution","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048384124","display_name":"John Tyson McDonald","orcid":"https://orcid.org/0000-0003-4300-6827","observed_orcids":["https://orcid.org/0000-0003-4300-6827"]},"institutions":[{"id":"https://openalex.org/I151328261","display_name":"Hampton University","ror":"https://ror.org/05fde5z47","country_code":"US","type":"education","lineage":["https://openalex.org/I151328261"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Tyson McDonald","raw_affiliation_strings":["Cancer Research Center, Hampton University, Hampton, VA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Research Center, Hampton University, Hampton, VA, USA","institution_ids":["https://openalex.org/I151328261"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077595545","display_name":"Afshin Beheshti","orcid":"https://orcid.org/0000-0003-4643-531X","observed_orcids":["https://orcid.org/0000-0003-4643-531X"]},"institutions":[{"id":"https://openalex.org/I1280536761","display_name":"Ames Research Center","ror":"https://ror.org/02acart68","country_code":"US","type":"facility","lineage":["https://openalex.org/I1280536761","https://openalex.org/I4210124779"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Afshin Beheshti","raw_affiliation_strings":["WYLE, NASA Ames Research Center, Moffett Field, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"WYLE, NASA Ames Research Center, Moffett Field, CA, USA","institution_ids":["https://openalex.org/I1280536761"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013911840","display_name":"Kevin A. David","orcid":"https://orcid.org/0000-0001-7415-0376","observed_orcids":["https://orcid.org/0000-0001-7415-0376"]},"institutions":[{"id":"https://openalex.org/I4390039325","display_name":"Rutgers Cancer Institute","ror":"https://ror.org/0060x3y55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4390039325"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kevin A. David","raw_affiliation_strings":["Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA","institution_ids":["https://openalex.org/I4390039325"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5064091455","display_name":"Andrew M. Evens","orcid":"https://orcid.org/0000-0002-6900-1824","observed_orcids":["https://orcid.org/0000-0002-6900-1824"]},"institutions":[{"id":"https://openalex.org/I4390039325","display_name":"Rutgers Cancer Institute","ror":"https://ror.org/0060x3y55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4390039325"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Andrew M. Evens","raw_affiliation_strings":["Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA"],"raw_orcid":"https://orcid.org/0000-0002-6900-1824","affiliations":[{"raw_affiliation_string":"Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA","institution_ids":["https://openalex.org/I4390039325"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5064091455"],"corresponding_institution_ids":["https://openalex.org/I4390039325"],"apc_list":{"value":3500,"currency":"USD","value_usd":3500},"apc_paid":null,"fwci":0.5512,"has_fulltext":true,"cited_by_count":14,"citation_normalized_percentile":{"value":0.66385145,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":98},"biblio":{"volume":"188","issue":"2","first_page":"295","last_page":"308"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.41190001368522644,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.41190001368522644,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11736","display_name":"Histone Deacetylase Inhibitors Research","score":0.23440000414848328,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.09099999815225601,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ixazomib","display_name":"ixazomib","score":1.0},{"id":"https://openalex.org/keywords/belinostat","display_name":"belinostat","score":1.0},{"id":"https://openalex.org/keywords/nrf2","display_name":"Nrf2","score":0.972000002861023},{"id":"https://openalex.org/keywords/proteasome-inhibition","display_name":"proteasome inhibition","score":0.7360000014305115},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.5730000138282776},{"id":"https://openalex.org/keywords/hodgkin-lymphoma","display_name":"Hodgkin's disease","score":0.8529999852180481},{"id":"https://openalex.org/keywords/t-cell-lymphoma","display_name":"T-cell lymphoma","score":0.9980000257492065},{"id":"https://openalex.org/keywords/histone-deacetylase-inhibitors","display_name":"histone deacetylase inhibitors","score":0.9169999957084656},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7419999837875366},{"id":"https://openalex.org/keywords/drug-synergy","display_name":"drug synergy","score":0.7860000133514404},{"id":"https://openalex.org/keywords/crispr-cas9-knockdown","display_name":"CRISPR/Cas9 knockdown","score":0.921999990940094}],"concepts":[{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.6525394320487976},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5996754169464111},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.52351313829422},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.4948098063468933},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.34119266271591187},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3056447505950928},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.19181329011917114},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.06724750995635986}],"mesh":[{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D001896","descriptor_name":"Boron Compounds","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D001896","descriptor_name":"Boron Compounds","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D004357","descriptor_name":"Drug Synergism","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005998","descriptor_name":"Glycine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D005998","descriptor_name":"Glycine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D005998","descriptor_name":"Glycine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D006689","descriptor_name":"Hodgkin Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006689","descriptor_name":"Hodgkin Disease","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D006689","descriptor_name":"Hodgkin Disease","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D006689","descriptor_name":"Hodgkin Disease","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006877","descriptor_name":"Hydroxamic Acids","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D006877","descriptor_name":"Hydroxamic Acids","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D015536","descriptor_name":"Down-Regulation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016399","descriptor_name":"Lymphoma, T-Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D016399","descriptor_name":"Lymphoma, T-Cell","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D016399","descriptor_name":"Lymphoma, T-Cell","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D016399","descriptor_name":"Lymphoma, T-Cell","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D017209","descriptor_name":"Apoptosis","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D019169","descriptor_name":"Jurkat Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051267","descriptor_name":"NF-E2-Related Factor 2","qualifier_ui":"Q000096","qualifier_name":"biosynthesis","is_major_topic":false},{"descriptor_ui":"D051267","descriptor_name":"NF-E2-Related Factor 2","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1111/bjh.16160","doi":"https://doi.org/10.1111/bjh.16160","is_oa":true,"landing_page_url":"https://doi.org/10.1111/bjh.16160","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.16160","source":{"id":"https://openalex.org/S153015021","display_name":"British Journal of Haematology","issn_l":"0007-1048","issn":["0007-1048","1365-2141"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Haematology","raw_type":"journal-article"},{"id":"pmid:31452195","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/31452195","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of haematology","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1111/bjh.16160","doi":"https://doi.org/10.1111/bjh.16160","is_oa":true,"landing_page_url":"https://doi.org/10.1111/bjh.16160","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.16160","source":{"id":"https://openalex.org/S153015021","display_name":"British Journal of Haematology","issn_l":"0007-1048","issn":["0007-1048","1365-2141"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Haematology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9537000060081482,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320310465","display_name":"Takeda Pharmaceutical Company","ror":"https://ror.org/04hjbmv12"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2970629241.pdf","grobid_xml":"https://content.openalex.org/works/W2970629241.grobid-xml"},"referenced_works_count":46,"referenced_works":["https://openalex.org/W1870662762","https://openalex.org/W1909862186","https://openalex.org/W1929921628","https://openalex.org/W1980471295","https://openalex.org/W1986020395","https://openalex.org/W2009402637","https://openalex.org/W2017556054","https://openalex.org/W2038994136","https://openalex.org/W2050169742","https://openalex.org/W2057290270","https://openalex.org/W2070814954","https://openalex.org/W2077945404","https://openalex.org/W2081446512","https://openalex.org/W2085144387","https://openalex.org/W2092648714","https://openalex.org/W2093401714","https://openalex.org/W2096367061","https://openalex.org/W2100614765","https://openalex.org/W2108300681","https://openalex.org/W2109371953","https://openalex.org/W2109716912","https://openalex.org/W2113805244","https://openalex.org/W2116068882","https://openalex.org/W2119544175","https://openalex.org/W2130410032","https://openalex.org/W2135658123","https://openalex.org/W2138271341","https://openalex.org/W2146112074","https://openalex.org/W2149386327","https://openalex.org/W2154083086","https://openalex.org/W2154475699","https://openalex.org/W2155324869","https://openalex.org/W2166766006","https://openalex.org/W2168980644","https://openalex.org/W2191026405","https://openalex.org/W2289881239","https://openalex.org/W2300290078","https://openalex.org/W2339869876","https://openalex.org/W2398350456","https://openalex.org/W2400628084","https://openalex.org/W2408743616","https://openalex.org/W2416844197","https://openalex.org/W2517817589","https://openalex.org/W2748958732","https://openalex.org/W2979508224","https://openalex.org/W4254421610"],"related_works":["https://openalex.org/W2980093565","https://openalex.org/W2561405819","https://openalex.org/W2300290078","https://openalex.org/W2572607142","https://openalex.org/W2273373802","https://openalex.org/W1538955534","https://openalex.org/W3096998980","https://openalex.org/W2093401714","https://openalex.org/W3092593035","https://openalex.org/W2979755397"],"abstract_inverted_index":{"Ixazomib":[0],"activity":[1,18,68,142,174,191],"and":[2,11,44,50,57,92,110,140,160,177,181,203],"transcriptomic":[3,139],"analyses":[4],"previously":[5],"established":[6],"in":[7,42,108,120,124,128,171,175,208],"T":[8],"cell":[9,129,179,210],"(TCL)":[10],"Hodgkin":[12],"(HL)":[13],"lymphoma":[14],"models":[15],"predicted":[16],"synergistic":[17,172,190],"for":[19,34],"histone":[20],"deacetylase":[21],"(HDAC)":[22],"inhibitory":[23],"combination.":[24],"In":[25,54,113],"this":[26],"present":[27],"study,":[28],"we":[29,153],"determined":[30],"the":[31,38,189],"mechanistic":[32],"basis":[33],"ixazomib":[35,132,148,166,193],"combination":[36],"with":[37,78,105,131,134],"HDAC":[39],"inhibitor,":[40],"belinostat,":[41,146],"HL":[43,58],"TCL":[45,56],"cells":[46,122],"lines":[47,180],"(ixazomib-sensitive/resistant":[48],"clones)":[49],"primary":[51,182],"tumour":[52],"cells.":[53,112,137,183],"ixazomib-treated":[55],"cells,":[59,152],"transient":[60],"inhibition":[61,199,206],"followed":[62],"by":[63,72,97,165],"full":[64],"recovery":[65,162,202],"of":[66,74,89,118,144,192],"proteasomal":[67,75,93,141,201,205],"observed":[69,154],"was":[70],"accompanied":[71],"induction":[73],"gene":[76,94,158],"expression":[77,95,159],"NFE2L2":[79,91,119],"(also":[80],"termed":[81],"NRF2)":[82],"as":[83],"a":[84,125],"prominent":[85],"upstream":[86],"regulator.":[87],"Downregulation":[88],"both":[90],"(validated":[96],"quantitative":[98],"real":[99],"time":[100],"polymerase":[101],"chain":[102],"reaction)":[103],"occurred":[104],"belinostat":[106,150,168,195],"treatment":[107],"Jurkat":[109,121],"L428":[111],"addition,":[114],"CRISPR/Cas9":[115],"mediated":[116,197],"knockdown":[117],"resulted":[123],"significant":[126],"decrease":[127],"viability":[130],"compared":[133],"untreated":[135],"control":[136],"Using":[138],"evaluation":[143],"ixazomib,":[145],"or":[147],"+":[149,167,194],"treated":[151],"that":[155,188],"NFE2L2,":[156],"proteasome":[157],"functional":[161],"were":[163],"abrogated":[164],"combination,":[169],"resulting":[170],"drug":[173],"ixazomib-sensitive":[176],"-resistant":[178],"Altogether,":[184],"these":[185],"results":[186],"suggest":[187],"is":[196],"via":[198],"NFE2L2-dependent":[200],"extended":[204],"culminating":[207],"increased":[209],"death.":[211]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":1},{"year":2020,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2019-09-05T00:00:00"}